The global cell-based assays market
comprises a large number of players and therefore the vendor landscape
is extremely fragmented. This scenario is expected to continue as an
increasing number of both biotechnology and pharmaceutical companies
enter into this market with their strong financial background, states
Transparency Market Research (TMR) in its latest research report. The
leading players within the global cell-based assays market are GE
Healthcare Inc., Charles River Laboratories, Danaher Corporation, Lonza
Group Ltd., Becton, Dickinson and Company, Merck & Co Company, Cell
Signaling Technology, Inc., Thermo fisher Scientific Inc., PerkinElmer
Inc., Marin Biologic Laboratories, Promega Corporation, Essen BioScience
Inc., BioAgilytix Labs., Cell Biologics Inc., Enzo Life Sciences, Inc.,
Selexis SA, Aurelia Bioscience Ltd., and QGel SA.
According to Transparency Market
Research, the global cell-based assays market will rise from US$13,576.7
mn in 2017 to US$19,710.7 mn by 2022, and expand at a 7.7% CAGR between
2017 and 2022. On the basis of geography, North America is estimated to
turn out to be the most lucrative regional market. North America is
estimated to exhibit a 7.5% CAGR during the forecast period from 2017 to
2022. By product, the reagents and consumables segment is leading and
it accounted for 32.1% of the total market in 2017. On the basis of
end-user, the pharmaceutical and biotechnology segment is anticipated to
lead.
Global Cell Based Assays Market.jpgHigh Demand From Pharmaceutical And Biotechnology Companies Driving Growth
One of the key factors boosting the
global cell-based assays is the rising prevalence of chronic diseases
such as cardiovascular diseases, cancer, diabetes, arthritis, and
epilepsy. The increasing availability of funding for research coupled
with huge support from governments are other factors boosting the growth
of this market. Of late, there has been a rising preference for cell
based essays on account of their ability to check for drug stability,
drug purification, and drug potency. This along with rising drug
discovery activities are helping the market to grow. Cell-based assays
are being used extensively by pharmaceutical and biotechnology companies
as they provide numerous possibilities to revolutionize the
therapeutics for life-threatening diseases such as cancer.
Restrictions Regarding Use Of Reagents To Pose A Challenge
The emergence of novel technologies in
science and medicine will also be a factor which is driving the growth
prospects of the cell-based assays market. The rising adoption of cell
based essay for high throughput screening methods such as drug
screening, in vitro testing methods for in vivo toxicity testing, and
newer branches of bioscience such as synthetic biology will boost the
growth prospect of this market. On the other hand, this market will be
restricted by the high cost of instruments. In addition to this, there
are several restrictions regarding the use of the reagents which will
also challenge the growth of the market to a certain extent.
No comments:
Post a Comment